City of Hope | Strategic Alliance Partners

February 09, 2024

An overview of promising novel cellular therapies showing efficacy against hematologic cancers in early-phase clinical trials.

February 09, 2024

The foundation of physician recommendations and medical/regulatory policy will be guided by the outcomes of published clinical research.

February 05, 2024

Multiple myeloma specialists compare step-up dosing practices and provide clinical insights on treating patients with multiple myeloma.

February 05, 2024

Experts on multiple myeloma discuss how real-world evidence informs treatment selection for patients receiving bispecific antibodies.

February 02, 2024

Provide detailed case studies highlighting the development, clinical presentation, multidisciplinary management, and outcomes of patients with acute and chronic GvHD following allo-HSCT.

January 31, 2024

Maurie Markman, MD, discusses the need for a decision support strategy to assist oncologists in treatment selection for patients with actionable mutations.

January 30, 2024

Alexey Danilov, MD, PhD, discusses the use of minimal residual disease to predict outcomes in patients with follicular lymphoma.

January 29, 2024

The innovative “fragmentomics” approach could one day allow doctors to identify cancer in patients sooner than possible today using smaller blood draws.

January 29, 2024

An expert panel reviews recent updates on BCMA-targeting bispecific antibodies in multiple myeloma.

January 29, 2024

Krina Patel, MD, reviews data from the CARTITUDE-4 and KarMMa-3 studies and shares perspectives on a potential role for CAR T-cell therapy at early relapse.

January 27, 2024

Focus on methods for preventing graft-versus-host disease (GvHD) following allo-HSCT, such as pharmacologic immune suppression and stem cell graft manipulation techniques.

January 27, 2024

Summarize ongoing and recently completed clinical trials related to allo-HSCT and associated therapies.

January 26, 2024

Ibrahim T. Aldoss, MD, discusses the use of revumenib monotherapy in patients with relapsed/refractory acute leukemia harboring KMT2A rearrangements.

January 23, 2024

The absence of clearly articulated definitions and transparency related to how clinical trial outcomes are interpreted and utilized raise concerns.

January 22, 2024

A panel of expert hematologic-oncologists offer insights on how they treat patients with multiple myeloma at early relapse.

January 22, 2024

The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.

January 22, 2024

Laleh Melstrom, MD, MS, discusses using molecular testing to guide treatment selection for patient with gastrointestinal cancers.

January 22, 2024

Afsaneh Barzi, MD, PhD, discusses the frontline use of FOLFOXIRI plus bevacizumab and subsequent therapies in patients with metastatic colorectal cancer.

January 19, 2024

Analyze risks and complications associated with allo-HSCT, including graft-versus-host disease, infections, relapse, and regimen-related toxicities.

January 19, 2024

This presentation will detail the supportive therapies and interventions provided to patients before, during, and after undergoing allo-HSCT. The speaker will also discuss management of treatment side effects and comorbidities to optimize patient outcomes.